Fig. 2
From: CKAP2L, a crucial target of miR-326, promotes prostate cancer progression
CKAP2L plays an oncogenic role in vitro and vivo. (A) CKAP2L mRNA and protein expression in BPH-1, 22Rv1, C4-2, PC-3, DU145 and LNCaP-AI cell lines. (B) CKAP2L expression in mRNA and protein level after shCKAP2L transfected in PC-3 and LNCaP-AI cells. (C) Silencing CKAP2L suppressed PC-3 and LNCaP-AI cells proliferation. (D, E) CKAP2L deletion inhibited cell migration and invasion ability in PC-3 and LNCaP-AI cells. (F) CKAP2L knockdown decreased monolayer colony formation ability of the prostate cancer cells. (G-I) Knockdown of CKAP2L by shRNA remarkably suppressed the xenograft formation according to the tumors weight and volume in nude mice compared with negative control. (J) Immunohistochemistry showed that compared with the control group, knocking down CKAP2L significantly decreased Ki-67 and in nude mouse tumors, while the expression of cleaved caspase-3 increased. *p < 0.05, ***p < 0.001